FDA label b21ca617-f7c6-4e18-96a8-5527b11e11bf

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
943d8700-e136-4c71-ac88-5fb323af95a1
SPL ID
b21ca617-f7c6-4e18-96a8-5527b11e11bf
Version
5
Effective date
2011-07-19
Source export date
2026-11-13
Source partition
3
Source file
https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/2df682709a18af7b632162dce4573ac151d74d432118e70b8675083d83b89813/drug-label-0003-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:50:54

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNING FLAMMABLE. AVOID FIRE, FLAME OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION. Keep out of reach of children. Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120ºF (49ºC). STIEFEL ® Manufactured for Stiefel Laboratories, Inc., a GlaxoSmithKline company RTP, NC 27709 USA PRASCO ® Distributed by Prasco Laboratories Mason, OH 45040 USA October 2009 304031 P/N: 129168 ©2009 Stiefel Laboratories, Inc., a GlaxoSmithKline company Printed in: US October 2009

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

ADVERSE REACTIONS In a controlled pharmacokinetic study, 5 of 13 subjects experienced reversible suppression of the adrenals at any time during the 14 days of clobetasol propionate foam, 0.05% therapy to at least 20% of the body surface area. Of the 13 subjects studied, 1 of 9 with psoriasis were suppressed after 14 days and all 4 of the subjects with atopic dermatitis had abnormal cortisol levels indicative of adrenal suppression at some time after starting therapy with clobetasol propionate foam, 0.05%. See Table 3 below. Table 3: Subjects with reversible HPA axis suppression at any time during treatment Dermatosis Clobetasol Propionate Foam, 0.05% Psoriasis 1 of 9 Atopic Dermatitis Clobetasol propionate foam, 0.05% is not indicated for non-scalp atopic dermatitis, as the safety and efficacy of clobetasol propionate foam, 0.05% in non-scalp atopic dermatitis has not been established. Use in children under 12 years of age is not recommended. 4 of 4 Systemic absorption of topical corticosteroids has produced reversible adrenal suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. See PRECAUTIONS . In a controlled clinical trial (188 subjects) with clobetasol propionate foam, 0.05% in subjects with psoriasis of the scalp, there were no localized scalp adverse reactions reported in the clobetasol propionate foam, 0.05% treated subjects. In two controlled clinical trials (360 subjects) with clobetasol propionate foam, 0.05% in subjects with psoriasis of non-scalp regions, localized adverse events that occurred in the clobetasol propionate foam, 0.05% treated subjects included application site burning (10%), application site dryness (<1%), and other application site reactions (4%). In larger controlled trials with other clobetasol propionate formulations, the most frequently reported local adverse reactions have included burning, stinging, irritation, pruritus, erythema, folliculitis, cracking and fissuring of the skin, numbness of the fingers, skin atrophy, and telangiectasia (all less than 2%). The following additional local adverse reactions have been reported with topical corticosteroids, but they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids such as clobetasol propionate foam, 0.05%. These reactions are listed in an approximate decreasing order of occurrence: dryness, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, and miliaria.

adverse reactions table

<table ID="_Refid_6878b532-10ad-47a2-b78e-8f4380e1b" width="100%"> <caption>Table 3: Subjects with reversible HPA axis suppression at any time during treatment</caption> <col width="20%"/> <col width="36%"/> <tbody> <tr> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>Dermatosis</paragraph> </td> <td align="center" styleCode="Rrule Botrule Toprule " valign="top"> <paragraph>Clobetasol Propionate Foam, 0.05%</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>Psoriasis</paragraph> </td> <td align="center" styleCode="Rrule Botrule " valign="top"> <paragraph>1 of 9</paragraph> </td> </tr> <tr> <td styleCode="Rrule Botrule Lrule " valign="top"> <paragraph>Atopic Dermatitis<footnote ID="_Refid-8a5c5186-72a4-4d11-89d8-81a41f652">Clobetasol propionate foam, 0.05% is not indicated for non-scalp atopic dermatitis, as the safety and efficacy of clobetasol propionate foam, 0.05% in non-scalp atopic dermatitis has not been established. Use in children under 12 years of age is not recommended.</footnote> </paragraph> </td> <td align="center" styleCode="Rrule Botrule " valign="top"> <paragraph>4 of 4</paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.